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phase II randomised clinical trial hypothesises that the bur-
den of hypo- and hyperoxia can be reduced by the com-
bined use of close monitoring of the cerebral rSt O 2 and a 
treatment guideline to correct deviations in rSt O 2 outside a 
predefined target range.  Aims: To describe the rationale for 
and content of this treatment guideline.  Methods: Review of 
the literature and assessment of the quality of evidence and 
the grade of recommendation for each of the interventions. 
 Results and Conclusions: A clinical intervention algorithm 
based on the main determinants of cerebral perfusion-oxy-
genation changes during the first hours after birth was gen-
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 Abstract 
 Near-infrared spectroscopy-derived regional tissue oxygen 
saturation of haemoglobin (rSt O 2 ) reflects venous oxygen 
saturation. If cerebral metabolism is stable, rSt O 2 can be used 
as an estimate of cerebral oxygen delivery. The SafeBoosC 
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erated. The treatment guideline is presented to assist neo-
natologists in making decisions in relation to cerebral oxim-
etry readings in preterm infants within the SafeBoosC phase 
II randomised clinical trial. The evidence grades were rela-
tively low and the guideline cannot be recommended out-
side a research setting.  © 2013 S. Karger AG, Basel 
 Introduction 
 Abnormal haemodynamic adaptation during the tran-
sitional circulation together with the impact of respira-
tory distress syndrome and related factors on blood flow 
distribution  [1] cause abnormalities in cerebral haemo-
dynamics and oxygen supply  [2–4] . Near-infrared spec-
troscopy (NIRS)-derived regional tissue oxygen satura-
tion of haemoglobin (rSt O 2 ) is an absolute value corre-
sponding to mixed blood saturation, and can be used as a 
surrogate measure for venous oxygen saturation  [5] . This 
allows the derivation of several variables related to tissue 
oxygen dynamics, such as oxygen delivery and consump-
tion and the ratio between oxygen delivery to oxygen ex-
traction, the so-called cerebral fractional oxygen extrac-
tion (FOE)  [5, 6] . Theoretically, therefore, this monitor-
ing system could help to adjust interventions with effects 
on blood and oxygen supply to the brain. 
 The SafeBoosC phase II randomised clinical trial hy-
pothesises that the burden of hypo- and hyperoxia can be 
reduced, and consequently the risk of brain injury, by the 
combined use of close monitoring of the cerebral rSt O 2 
and an evidence-based treatment guideline to correct de-
viations in rSt O 2 outside a predefined target range  [7–9] . 
Accordingly, a treatment guideline has been developed fo-
cusing on interventions that could have an impact on arte-
rial oxygen saturation (Sa O 2 ), haemoglobin concentra-
tion, and cerebral blood flow (CBF), which are the main 
determinants of oxygen delivery to the brain. The purpose 
of this report is to describe the rationale for this treatment 
guideline and the treatment recommendations.
 Interventions That Affect Oxygen Delivery to the 
Brain 
 In drawing up the treatment guideline we used the 
premise that hypoxia and hyperoxia are risk factors for an 
adverse outcome in the preterm infant and should be 
avoided  [10–15] . In addition to NIRS assessment of the 
cerebral circulation, a number of other techniques, par-
ticularly echocardiography, are used to assess the neona-
tal transitional circulation and related outcomes  [1, 16–
27] . For the purposes of the treatment guideline, a sys-
tematic review of the literature was carried out focusing 
on clinical studies conducted on human neonates that 
used NIRS-derived variables as outcome measures sup-
porting the statements listed in the treatment guideline 
for intervention in the SafeBoosC phase II randomised 
clinical trial. The literature review was conducted in 
March 2011 using the database PubMed and subject 
headings (MeSH terms). There were no date restrictions. 
The search board was kept to combine the concept of a 
neonate (or newborn) with the concepts of NIRS and 
cerebrovascular circulation. In addition, blood pressure, 
hypotension, dopamine, dobutamine, epinephrine, anae-
mia, blood transfusion, carbon dioxide, respiratory dis-
tress syndrome, patent ductus arteriosus (PDA) and 
treatment, and blood glucose were also combined with 
the terms NIRS and newborn. This search was supple-
mented by cross references. Two hundred and twenty- 
nine abstracts were selected for review; among them, only 
27% were relevant for the issues to be addressed in the 
treatment guideline. Only 4% of the selected studies were 
randomised clinical trials. 
 The proposed treatment guideline for the SafeBoosC 
phase II randomised clinical trial is based on interven-
tions that may optimise cerebral oxygen supply and con-
sumption through factors such as perfusion pressure, 
ventricular output, arterial oxygen content, arterial car-
bon dioxide, or blood glucose concentration. We assume 
a rather steady cerebral metabolic rate of oxygen. Given 
that the SafeBoosC intervention period focuses on the 
first 3 days after an extremely low gestational age neonate 
is born  [8, 9] , disease states and related factors most com-
monly present during that period were of particular inter-
est. The definition of normal range for cerebral rSt O 2 in 
this trial (55–85%) was derived from Lemmers and van 
Bel [unpubl. data] as the 95% CI of rSt O 2 monitoring of 
439 preterm infants born at <32 weeks during the first 3 
days after birth using INVOS and the Adult SomaSensor 
(Somanetics-Covidien, Dublin, Ireland). The application 
of the adult sensor in this population is considered safe as 
no serious adverse device effects, such as skin burns, were 
found in these infants. Device eligibility will be tested by 
comparison of absolute values, reproducibility, and sen-
sitivity to changes in oxygenation on the adult arm  [28] . 
Absolute values and dynamic range within 5 percentage 
points of INVOS and reproducibility better than 6% are 
the predefined thresholds. So far, eligible devices for the 
SafeBoosC trial include INVOS 5100C with the Adult
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SomaSensor, NIRO 200NX (Hamamatsu Photonics, Fu-
kuoka, Japan) with a small probe holder, and OxyPrem, 
a prototype developed by investigators in the SafeBoosC 
trial (M.W.). 
 We developed a pathophysiologically oriented, evi-
dence-based treatment guideline and assessed the level of 
recommendation according to the US Preventive Services 
Task Force (USPSTF) System from 2001  [29] (Appen-
dix). A new version of the USPSTF system is currently in 
use  [30] where the wording of the grade C recommenda-
tion is possibly the most important change with respect 
to the previous version; it reads: ‘... against routinely pro-
viding X service for Y population; there may be consider-
ations that support providing the service in an individual 
patient’. One of the actions listed in the present treatment 
guideline (i.e. volume expansion with normal saline) has 
been classified as a grade C recommendation. This, as 
well as the remaining actions included, is a suggested but 
not mandated intervention, and all of them should be 
considered individually according to the patient’s overall 
clinical condition. Newer developments for grading the 
quality of evidence and the strength of recommendations 
 [31] are more rigorous, but also more complex and time 
consuming. We, therefore, adhered to the USPSTF sys-
tem due to its relative ease of use.
 If rSt O 2 falls out of the normal range (55–85%) and 
there is no reason to believe that it will normalise without 
an intervention, this treatment guideline aims to bring a 
standardised approach to correct the deviation. As the ef-
fect of certain interventions, such as the effect of cardio-
vascular drugs on blood pressure, are not expected to be 
immediate, it is recommended to choose only one inter-
vention at a time and reassess after 30–60 min. It must be 
kept in mind that many routine care-giving procedures
in the neonatal intensive care unit, such as handling or 
change in posture  [32, 33] , endotracheal tube reposition-
ing or suctioning  [32] , or blood sampling from umbilical 
lines  [34–36] , among others, may have an impact on ce-
rebral haemodynamics and oxygenation. However, since 
NIRS changes determined by these factors are usually 
transient and can be anticipated, they have not been listed 
in this treatment guideline.
 Online supplementary figure 1 (for all online suppl. 
 material, see www.karger.com/doi/1159/000351346) shows 
an algorithm that describes the flow of suggested inter-
ventions in the SafeBoosC trial when rSt O 2 is out of the tar-
get range. 
 rSt O 2 below the threshold may reflect compromised 
oxygen delivery. The proposed interventions are directed 
to increasing CBF, oxygen transport capacity, or blood 
oxygen content. Accordingly, the assessment of cardio-
vascular status, haemoglobin concentration, and Sa O 2 
should be done before an intervention is chosen.
 Assessment/Interventions Related to Cardiovascular 
Status 
 Changes in rSt O 2 or FOE may follow changes in cere-
bral perfusion pressure in infants with haemodynamic in-
stability, which may  [37–39] or may not  [40–42] be re-
flected by concordant changes in mean arterial blood 
pressure. Thus, this treatment guideline would suggest to 
check the cardiovascular system, primarily considering 
clinical variables available in routine clinical practice, 
such as blood pressure, blood lactate concentration, cap-
illary refill time, or urine output to define whether com-
promised systemic circulation is present or not. Echocar-
diography-derived variables on blood flow distribution, 
such as cardiac output and superior vena cava flow mea-
surements, may be of value as complementary assess-
ments to indicate or guide intervention. 
 Administration of fluid bolus, vasopressor-inotropes 
(dopamine or epinephrine), or inotropes (dobutamine), 
has a variable effect on blood pressure, cardiac perfor-
mance, and cerebral perfusion-oxygenation  [16–20, 43] . 
The effect of volume expansion on rSt O 2 has not been 
systematically explored in infants. However, a recent ran-
domised clinical trial has shown that delayed cord clamp-
ing increases cerebral rSt O 2 at 4 and 24 h after birth in 
preterm infants  [44] . This early increase in preload pos-
sibly ameliorates cardiovascular maladaptation during 
transitional circulation  [45] .
 Studies in neonates have shown that dopamine  [38, 
43] and epinephrine  [43] , given to treat early systemic 
hypotension, increase cerebral perfusion-oxygenation. 
The 2-year follow-up of the study population showed 
comparable outcomes in vasopressor-inotrope-treated 
infants and infants who did not develop hypotension and 
thus did not receive cardiovascular support early after 
birth  [16] . However, cautious use of vasopressors is rec-
ommended, as increased afterload may further compro-
mise myocardial contractility causing additional decrease 
in cardiac output  [1] , and consequently, worsening cere-
bral perfusion. 
 The effect of a haemodynamically significant PDA or 
its treatment on cerebral haemodynamics and oxygen-
ation is addressed in a number of studies using NIRS and 
other monitoring methods  [46–61] . PDA may be a deter-
minant in blood flow redistribution causing decreased 
blood pressure and rSt O 2 and increased FOE  [57] . How-
ever, no correlation was found between ductal size and 
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rSt O 2  [60] . Treatment of PDA may also be relevant for the 
rSt O 2  [57] . Indomethacin has been shown to have an 
acute greater impact on cerebral perfusion and oxygen-
ation  [47, 49, 52, 58, 59] than ibuprofen  [51, 52] . How-
ever, slower infusion rates did not have such an impact 
on brain haemodynamics  [61] . Surgical closure of the 
PDA showed no consistent effects on cerebral circulation 
and oxygenation  [53–56] . 
 Finally, mechanical factors, particularly lung overinfla-
tion, may decrease preload and cause increased pulmo-
nary vascular resistance. Both factors would impair myo-
cardial function and cardiac output  [22–25] . This condi-
tion should always be ruled out in case of decreasing rSt O 2 .
 Assessment/Interventions Related to Oxygen 
Transport (Blood Oxygen Carrying Capacity) 
 Although there is no clear correlation between haemo-
globin concentration and tissue oxygen extraction  [62, 
63] , packed-red cell transfusion improves cerebral oxy-
genation in the anaemic preterm infant  [63–65] . In addi-
tion, a randomised clinical trial has shown that placental-
to-foetal transfusion increases rSt O 2  [44] , possibly not 
only due to increased oxygen carrying capacity but also to 
improved preload. A positive effect of this procedure on 
superior vena cava flow has been recently reported  [45] .
 Assessment/Interventions Related to Respiratory 
Status 
 Infants with respiratory distress syndrome have a sig-
nificantly larger range of cerebral rSt O 2 and FOE and a 
stronger relation between these cerebral haemodynamic 
variables and mean arterial blood pressure than infants 
without respiratory distress syndrome  [66] . One of the 
most important determinants of CBF and cerebral oxy-
gen dynamics is partial pressure of carbon dioxide (P CO 2 ) 
 [46, 63, 67–70] . It is crucial, because inadvertent hyper-
ventilation may occur as a result of mechanical ventila-
tion during the acute phase of respiratory distress syn-
drome. If P CO 2 is below the normal range or low, even in 
the normal range, we recommend considering to decrease 
minute ventilation in case of low rSt O 2  [63, 67–69] . Since 
the effect of manipulating minute ventilation on rSt O 2 has 
not been tested in a randomised trial, the evidence level 
in this guideline is only II. The understanding of the me-
chanics and physiology, as well as the epidemiological 
link between hyperventilation and brain injury and cere-
bral palsy, however, may be seen as sufficient for a stron-
ger recommendation (A).
 The effect of the type of mechanical ventilation or air-
way pressure on the cerebral haemodynamics and oxy-
genation by NIRS has been the focus of some small obser-
vational studies in newborns  [71–75] . The way these dif-
ferent methods affect intrathoracic pressures would 
likely impact the cerebral and systemic circulation of im-
mature neonates  [76] .
 This treatment guideline has been modified after a pi-
lot trial  [77] to specifically warn against exceeding the up-
per threshold of Sa O 2 according to local policies. There-
fore, the fractional inspired oxygen fraction (Fi O 2 ) should 
only be increased if Sa O 2 is below the normal range or low, 
even in the normal range  [10] . Other potential actions 
relate to increasing Sa O 2 through improvement in lung 
recruitment by moderate increase in mean airway pres-
sure  [22, 26, 75] . 
 rSt O 2 increasing above the upper normal limit may re-
flect impaired oxygen utilisation or disturbed cerebral au-
toregulation, and interventions should be directed at de-
creasing hyperaemia. The assessment of respiratory sta-
tus and blood glucose content should be done before an 
intervention is chosen.
Assessment/Interventions Related to Respiratory 
Status
 The first step would be decrease Fi O 2 in case Sa O 2 is 
above the normal range or high, even in the normal 
range  [11–15] . Additional interventions would be to de-
crease mean airway pressure  [26, 75] . The vasodilator 
effect of P CO 2 should be considered, so minute ventila-
tion should be increased in case of P CO 2 above the nor-
mal range or high, even in the normal range, to lower 
P CO 2  [63, 67–69] .
 Assessment of Blood Glucose Level 
 Hypoglycaemia would be the cause of capillary re-
cruitment and increased CBF  [27, 78] . Thus, if the blood 
glucose level is below the normal range or low, even in the 
normal range, increased glucose intake should be consid-
ered to raise blood glucose concentration.
 Conclusion 
 This treatment guideline for the SafeBoosC phase II 
trial aims to help neonatologists to take decisions in rela-
tion to cerebral oximetry readings. None of the suggested 
actions are mandatory. The proposed clinical interven-
tion algorithm is focused on the main determinants of 
cerebral perfusion-oxygenation changes during the first 
hours after birth in the extremely low gestational age
neonate population, and is thus pathophysiologically 
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oriented. The evidence supporting some of these state-
ments is generally rather weak. The proposed interven-
tions, however, are all routinely used in clinical care of 
these patients. Particular care has been taken on hyper-
ventilation with low P CO 2 and oxygen administration 
with high Sa O 2 due to their association with adverse out-
comes. We stress that this guideline is not approved for 
general use outside randomised clinical trials. We look 
forward to be able to report the results of the present 
SafeBoosC phase II randomised clinical trial and the 
planned SafeBoosC phase III randomised clinical trial 
that will evaluate the combined effect of NIRS and this 
treatment guideline  [8, 9] .
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 Appendix 
 SafeBoosC Trial Treatment Guideline 
rStO2 <55%
Assess cardiovascular status
Blood pressure below the normal range or low, even in the normal range, 
consider:
Vasopressor-inotropes (I/B) [16, 43]
Fluid bolus (normal saline) (I/C) [17, 18]
Decrease mean airway pressure (III/B) [22–25]
Poor systemic circulation, consider if:
Echocardiography shows low cardiac output and/or low superior vena cava 
flow
Inotropes (I/B) [18–20, 40–42]
Fluid bolus (normal saline) (I/C) [17, 18]
Decrease mean airway pressure (III/B) [22–25]
Reduce vasopressor (III/B) [1]
Echocardiography not available but has at least two of the following signs:
Lactate >3.5 mmol/l
CRT >3 s
Urine output <1 ml/kg/h
Consider:
Inotropes (I/B) [18–20, 40–42]
Fluid bolus (normal saline) (I/C) [17, 18]
Decrease mean airway pressure (III/B) [22–25]
Reduce vasopressor (III/B) [1]
PDA, consider:
Medical treatment (II-2/B) [21, 23, 24, 57]
Assess oxygen transport
Haemoglobin below the normal range or low, even in the normal range, 
consider:
Red blood cell transfusion (I/B) [44, 63–65]
Assess respiratory status
SaO2 below the normal range or low, even in the normal range, consider:
Increase FiO2 (II-1/A) [10] (attention: be careful not to exceed the 
upper target threshold of SaO2)
Increase mean airway pressure (III/B) [22, 26, 75]
PCO2 below the normal range or low, even in the normal range, consider:
Decrease minute ventilation (II-2/A) [63, 67–69]
rStO2 >85%
Assess respiratory status
SaO2 above the normal range or high, even in the normal range, consider:
Decrease FiO2 (II-2/A) [11–15]
Decrease mean airway pressure (III/B) [26, 75]
PCO2 above the normal range or high, even in the normal range, consider:
Increase minute ventilation (II-2/A) [63, 67–69]
Assess blood glucose level
Blood glucose <2.5 mmol/l, consider:
Increase glucose intake (II-2/A) [27, 78]
The recommendation according to the US Preventive Services Task 
Force (USPSTF) System for 20001 [29]. The Roman number refers to the 
level of evidence hierarchy the recommendation originates from (I; II-1; II-2; 
II-3; III) and the letter is our recommendation according to the USPSTF 
grading (A; B; C; D; I).
Level of 
evidence 
Type of study
I evidence obtained from at least one properly
randomised controlled trial
II-1 evidence obtained from well-designed controlled 
trials without randomisation
II-2 evidence obtained from well-designed cohort or
case-control analytic studies, preferably from more 
than one centre or research group
II-3 evidence obtained from multiple time series with
or without intervention; dramatic results in
uncontrolled experiments (such as the results of the 
introduction of penicillin treatment in the 1940s)
can also be regarded as this type of evidence
III opinions of respected authorities, based on clinical 
experience, descriptive studies and case reports, or 
reports of expert committees
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Quality of evidence  Net benefit
subs tantial moderate small zero/negative
Good A B C D
Fair B B C D
Poor = I
Standard recommendation 
language
A = strongly recommended (good evidence that the intervention improves important health outcomes 
and benefits substantially outweigh harms)
B = recommended (at least fair evidence that the intervention improves important health outcomes and 
benefits substantially outweigh harms)
C = no recommendation for or against routine provision of the intervention (fair evidence that the 
service can improve health outcomes but the balance of the benefits and harms is too close to justify a 
general recommendation)
D = recommends against routinely providing the intervention (at least fair evidence that the service is 
ineffective or that harms outweigh benefits)
I = insufficient to recommend for or against routinely providing the intervention (evidence that the 
intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms 
cannot be determined)
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